NCT06661733View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

December 23, 2024

Study Completion Date

December 23, 2024

Conditions
Renal Impairment
Interventions
DRUG

AZD5462

Participants will receive AZD5462 orally.

Trial Locations (1)

1612

Research Site, Sofia

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY